Voss, Martin

Publications

Sort by

Co-Author Network

selected publications

A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 Academic Article GET IT
Times cited: 20
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 648
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, N.Y.). 2018 Academic Article GET IT
Times cited: 689
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic oncology. 2017 Academic Article GET IT
Times cited: 19
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Investigational new drugs. 2017 Academic Article GET IT
Times cited: 10
Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome biology. 2017 Academic Article GET IT
Times cited: 7
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 17
Genome-Driven Paradigm for the Development of Selective Fibroblast Growth Factor Receptor Inhibitors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Times cited: 6
Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome biology. 2016 Academic Article GET IT
Times cited: 519
Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 57
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European urology. 2016 Academic Article GET IT
Times cited: 151
Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. Nature communications. 2016 Academic Article GET IT
Times cited: 120
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 703
Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European urology focus. 2016 Academic Article GET IT
Times cited: 27
Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer immunology research. 2016 Academic Article GET IT
Times cited: 55
Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European urology focus. 2016 Academic Article GET IT
Times cited: 31
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nature reviews. Urology. 2016 Review GET IT
Times cited: 78
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2016 Academic Article GET IT
Times cited: 54
Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. British journal of cancer. 2016 Academic Article GET IT
Times cited: 38
Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. 2015 Academic Article GET IT
Times cited: 15
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 6
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist. 2015 Academic Article GET IT
Times cited: 36
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2015 Academic Article GET IT
Times cited: 19
Challenging the treatment paradigm for advanced renal cell carcinoma: a review of systemic and localized therapies. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2015 Review GET IT
Times cited: 9
Safety and efficacy of targeted therapy for renal cell carcinoma with brain metastasis. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 33
Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. The American journal of surgical pathology. 2014 Academic Article GET IT
Times cited: 184
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 173
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Annals of oncology : official journal of the European Society for Medical Oncology. 2014 Academic Article GET IT
Times cited: 66
An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 191
Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 260
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. Cancer. 2013 Academic Article GET IT
Times cited: 29
Novel approaches targeting the vascular endothelial growth factor axis in renal cell carcinoma. Cancer journal (Sudbury, Mass.). 2013 Review GET IT
Times cited: 9
Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience. Clinical lymphoma, myeloma & leukemia. 2012 Academic Article GET IT
Times cited: 58
Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. European urology. 2012 Academic Article GET IT
Times cited: 173
Importance of day 21 BM chimerism in sustained neutrophil engraftment following double-unit cord blood transplantation. Bone marrow transplantation. 2011 Academic Article GET IT
Times cited: 10
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2011 Academic Article GET IT
Times cited: 99
Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors. Onkologie. 2011 Editorial Article GET IT
Times cited: 3
mTOR inhibitors in advanced renal cell carcinoma. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 97
High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert review of anticancer therapy. 2011 Review GET IT
Times cited: 13
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematology/oncology clinics of North America. 2011 Review GET IT
Times cited: 12

more ...

less ...

Background

education and training

M.D., Albert-Ludwig University (Germany) 2005

Contact

full name

Martin Voss

VIVO Weill Cornell Medical College

Martin Voss Associate Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name